We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How has the bipolar disorder drugs and treatment grown historically, and what trends indicate future expansion?
The bipolar disorder drugs and treatment market size has grown strongly in recent years. It will grow from $7.74 billion in 2024 to $8.24 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing healthcare expenditure, rising mental health research and funding, increasing number of healthcare professionals specializing in mental health, increasing number of bipolar disorder patients being diagnosed early, and growing need for outpatient psychiatric care.
The bipolar disorder drugs and treatment market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing prevalence of bipolar disorder worldwide, rising awareness about mental health conditions, growing acceptance of mental health treatment, expansion of insurance coverage for mental health treatments, and government initiatives to improve mental health care. Major trends in the forecast period include advancements in drug development for bipolar disorder, improvement in diagnostic methods and tools, introduction of new and innovative drug formulations, ongoing clinical trials and research on novel drugs, and availability of generic bipolar disorder medications.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24171&type=smp
Which key factors are driving the expansion of the bipolar disorder drugs and treatment industry?
The increasing prevalence of mental health disorders is anticipated to fuel the growth of the bipolar disorder drugs and treatment market in the coming years. Mental health disorders are conditions that affect a person’s thinking, feeling, behavior, or mood, often impairing daily functioning and well-being. Mental health disorders are rising due to increasing chronic stress from modern lifestyles, as ongoing pressures related to work, finances, and societal demands can erode emotional well-being and lead to long-term psychological challenges. Bipolar disorder drugs and treatment are beneficial for mental health disorders as they help stabilize mood fluctuations, which is essential for improving emotional regulation and reducing the frequency and severity of disruptive episodes associated with these conditions. For instance, in September 2024, according to the National Institute of Mental Health (NIMH), a US-based federal agency, any mental illness (AMI) affected over 59.3 million adults in the US in 2022, accounting for 23.1% of the adult population. Furthermore, women were much more likely than men to have AMI (26.4%) compared to 19.7%. Therefore, the increasing prevalence of mental health disorders will drive the growth of the bipolar disorder drugs and treatment market.
How is the bipolar disorder drugs and treatment market segmented by product, application, and end-user?
The bipolar disorder drugs and treatment market covered in this report is segmented –
1) By Types: Mood Stabilizers, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs, Anti-Anxiety Drugs
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Bipolar Disorder: Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Mood Stabilizers: Lithium Carbonate, Lamotrigine, Valproate
2) By Anticonvulsants: Carbamazepine, Oxcarbazepine, Topiramate
3) By Antipsychotic Drugs: Olanzapine, Risperidone, Quetiapine, Aripiprazole
4) By Antidepressant Drugs: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs)
5) By Anti-Anxiety Drugs: Benzodiazepines, Buspirone
View The Full Market Report:
Which major trends are influencing the growth of the bipolar disorder drugs and treatment industry?
Major companies operating in the bipolar disorder drugs and treatment market are focusing on developing advanced solutions, such as extended-release injectable formulations, to provide consistent and long-term therapeutic effects. Extended-release injectable formulations refer to treatments that slowly release medication into the bloodstream over time, reducing the need for daily dosing and promoting consistent therapeutic effects. For instance, in January 2023, Luye Pharma, a China-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for Rykindo (risperidone), a long-acting injectable suspension to treat adult schizophrenia and as a stand-alone treatment or in combination with lithium or valproate to treat adult bipolar I disorder. It utilizes a unique microsphere technology platform developed by Luye Pharma. This drug is administered through an intramuscular injection every two weeks, providing long-acting effects. The active ingredient, risperidone, is delivered via extended-release microsphere technology, ensuring sustained release over time.
Which leading companies are dominating the bipolar disorder drugs and treatment market landscape?
Major companies operating in the bipolar disorder drugs and treatment market are Pfizer Inc., Johnson & Johnson, Merch & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Sumitomo Pharma America Inc., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Neurocrine Biosciences Inc., Alkermes Plc.
Which geographic areas are expected to offer the highest growth opportunities in thebipolar disorder drugs and treatment market?
North America was the largest region in the bipolar disorder drugs and treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder drugs and treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Bipolar Disorder Drugs And Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24171&type=smp
Need Customized Data On Bipolar Disorder Drugs And Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24171&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
